DIABETIC MACULAR EDEMA

This study tests a new medicine called BI 3812465 for people with diabetic macular edema, a condition that causes swelling in the center of the eye and can lead to vision loss. The trial has two parts: first, a small group gets low to high doses to check safety, then a larger gro…

This early-stage trial tests an experimental drug called RO7823653, given as an eye injection alone or with an approved drug (faricimab), for people with diabetic macular edema—a condition where diabetes causes fluid buildup and vision loss in the center of the eye. The study wil…

This trial investigates whether people with diabetic macular edema can safely monitor their vision and eye health at home instead of making frequent hospital visits. Participants use a home vision tester and a portable eye scanner every four weeks, with results sent to their doct…

This study tests a new medicine, EYP-1901, given as an eye injection to people with diabetic macular edema (DME), a condition that causes blurry vision in people with diabetes. The goal is to see if EYP-1901 works as well as the standard treatment (aflibercept) but with fewer inj…

This phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision …

This study tests a new medicine called AVT29 against an approved drug, Eylea HD, for people with diabetic macular edema (DME), a leading cause of vision loss in diabetes. About 256 adults with DME will receive either AVT29 or Eylea HD to see if AVT29 works just as well at improvi…

This early-phase trial is testing an oral drug called Kamuvudine-9 (K9) in 10 adults with diabetic macular edema, a condition that causes vision loss. The study aims to see if K9 is safe and whether it improves vision compared to a placebo. Participants will take either K9 or pla…

This early-stage trial tests a new drug called OCU200, given as an injection into the eye, for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). The study will include 24 participants and will primarily check for safety and side effects…

This study compares having one laser treatment versus several sessions for a serious diabetic eye condition that can cause blindness. Researchers want to see which approach is safer and works better. The study will involve 40 adults with type 1 or type 2 diabetes who have this ey…

This study tests whether levosulpiride, a drug already used for other conditions, can safely improve vision and reduce retinal swelling in people with diabetic retinopathy and diabetic macular edema. About 120 adults aged 40-69 with mild to moderate eye damage will receive either…

This early-stage trial tests an oral drug called MS-553 in 45 people with diabetic macular edema, a condition that causes vision loss in people with diabetes. Participants take the drug daily for 8 weeks. The main goal is to check safety, but researchers will also measure changes…

This study compares two ways of screening for diabetic eye disease: using artificial intelligence to read retinal photos versus having eye doctors review them. About 922 adults with diabetes will get their eyes photographed in a primary care clinic. The goal is to see if AI can m…

This study will analyze health records from 2009 to 2024 to find out how many people in Germany have three serious eye conditions: wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Researchers will look at data from two large German health …

This study tracks eye pressure in 100 people receiving a larger-volume injection of Aflibercept (0.07mL) for macular diseases like age-related macular degeneration. Researchers measure pressure right after the injection and at several time points, then check for any nerve damage …

This study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab (VABYSMO) in routine clinical practice. Over two years, researchers will track vision changes, treatment schedules, and sa…

This study is for people with diabetic macular edema, a condition that causes vision loss. Researchers want to see if certain substances in the blood and patterns on eye scans can predict how well a patient will respond to two common treatments: anti-VEGF injections or a dexameth…